Boiron S.A.

Boiron manufactures and markets homeopathic medicines. Homeopathic medicines are prepared from vegetable, animal, mineral, or chemical substances, which are diluted. Co. sells three types of products in 59 countries: Non-proprietary homeopathic medicines, OTC family medication specialties, and Other products. There are two large families of homeopathic medicines: Those associated with precise therapeutic indications and dosage, and those that do not mention a therapeutic indication or dosage. Co. supports homeopathy education and training organizations for healthcare professionals. Some of Co.'s brand names include Oscillococcinum®, Stodal®, S?datif PC®, and Coryzalia.
  • TickerBOI
  • ISINFR0000061129
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Alain William ...
  • Antoine Boivin-Champeaux
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Benoit Valleaux
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Fatma Ayachi
  • Fatma Agnès Hamdani
  • Fehmi Ben Naamane
  • Jeremy Garnier
  • Johanna Jourdain
  • Michael Foundoukidis
  • Nicolas David
  • Nicolas Thorez
  • Olivier Lebrun
  • Roland Pfaender
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 19/07/2019

La nouvelle stratégie, dont Ben Smith consolide actuellement méthodiquement les fondations, pourrait apporter un supplément net de 200 pb de marge EBIT (vs 4.6% en 2019) grâce à l’activation de leviers à la main du management à horizon 3 ans. Une adhésion des pilotes rendrait possible une évolution en profondeur et une appréciation des multiples avec un best case ajoutant 20 € à notre OC. Achat réitéré. Le titre fait partie de notre liste de Convictions large caps. - ...

Alain William ...
  • Antoine Boivin-Champeaux
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Benoit Valleaux
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Fatma Ayachi
  • Fatma Agnès Hamdani
  • Fehmi Ben Naamane
  • Jeremy Garnier
  • Johanna Jourdain
  • Michael Foundoukidis
  • Nicolas David
  • Nicolas Thorez
  • Olivier Lebrun
  • Roland Pfaender
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 07/19/2019

The new strategy, the foundations of which Ben Smith is methodically consolidating, could add an extra 200bp of EBIT margin (vs. 4.6% in 2019) thanks to the activation of the levers in management’s hands over the next three years. Support from the pilots would facilitate a radical change and a re-rating with a best case adding € 20 to our target price. Buy recommendation reiterated. The stock is part of our Large Cap Convictions List. - - ...

Christophe-Raphaël Ganet

Boiron : France penalises Q2 sales. Marked downward revision to guidance for underlying operating profit. Visibility still very limited. Forecasts and TP cut

>Q2: -6.4%, primarily due to France - Q2 sales were down 6.4% (67.2% cc): i/ down -12% in France (-9% in Q1), ii/ up 14% in the US (vs 0% in Q1 due to a demanding comparison based stemming from the +87% posted in Q1 2018) and iii/ down 5% at subsidiaries in Europe (vs 0% in Q1 / continued pressure in Spain). This decline primarily stemmed from France were sales were down 12.0%. Excluding France, sales were up 3.5%.For H1, consolidated sales were down 8.5% (-9.2% ...

Christophe-Raphaël Ganet

Boiron : La France pénalise le CA T2. Une guidance de ROC en forte baisse. Visibilité toujours très limitée. Prévisions et OC abaissés

>T2 : -6,4%, essentiellement en raison de la France - Le CA T2 affiche un recul de 6,4% (67,2% à tcc) : i/ la France est en baisse de 12% (-9% au T1), ii/ les USA sont en hausse de 14% (vs 0% au T1 qui subissait un fort effet de base compte tenu du +87% enregistré au T1 2018), iii/ les filiales Europe sont en baisse de 5% (vs 0% au T1 / poursuite de la pression en Espagne). Cette baisse provient donc essentiellement de la France où les ventes ont reculé de 12,0 %. Hor...

Christophe-Raphaël Ganet ...
  • Jean-François Granjon
  • Philippe Ourpatian

ODDO BHF Small & MIDCAP MORNING NEWS - 06/28/2019

We are initiating coverage of SMCP, one of the world leaders in accessible luxury with a Buy recommendation and a target price of € 20.5. The group is known for delivering steady growth in each of its three brands. Taking the best of both worlds, it combines the benefits of luxury and fast fashion. We see the current valuation as an investment opportunity (EV/EBITDA 2019 of 6.3x, 30% discount vs. peers) in light of the group’s solid financial profile and significant growth potential, ...

Alain William ...
  • Antoine Boivin-Champeaux
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Benoit Valleaux
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Fatma Ayachi
  • Fatma Agnès Hamdani
  • Fehmi Ben Naamane
  • Jeremy Garnier
  • Johanna Jourdain
  • Michael Foundoukidis
  • Nicolas David
  • Nicolas Thorez
  • Olivier Lebrun
  • Roland Pfaender
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 19/07/2019

La nouvelle stratégie, dont Ben Smith consolide actuellement méthodiquement les fondations, pourrait apporter un supplément net de 200 pb de marge EBIT (vs 4.6% en 2019) grâce à l’activation de leviers à la main du management à horizon 3 ans. Une adhésion des pilotes rendrait possible une évolution en profondeur et une appréciation des multiples avec un best case ajoutant 20 € à notre OC. Achat réitéré. Le titre fait partie de notre liste de Convictions large caps. - ...

Alain William ...
  • Antoine Boivin-Champeaux
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Benoit Valleaux
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Fatma Ayachi
  • Fatma Agnès Hamdani
  • Fehmi Ben Naamane
  • Jeremy Garnier
  • Johanna Jourdain
  • Michael Foundoukidis
  • Nicolas David
  • Nicolas Thorez
  • Olivier Lebrun
  • Roland Pfaender
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 07/19/2019

The new strategy, the foundations of which Ben Smith is methodically consolidating, could add an extra 200bp of EBIT margin (vs. 4.6% in 2019) thanks to the activation of the levers in management’s hands over the next three years. Support from the pilots would facilitate a radical change and a re-rating with a best case adding € 20 to our target price. Buy recommendation reiterated. The stock is part of our Large Cap Convictions List. - - ...

Christophe-Raphaël Ganet

Boiron : France penalises Q2 sales. Marked downward revision to guidance for underlying operating profit. Visibility still very limited. Forecasts and TP cut

>Q2: -6.4%, primarily due to France - Q2 sales were down 6.4% (67.2% cc): i/ down -12% in France (-9% in Q1), ii/ up 14% in the US (vs 0% in Q1 due to a demanding comparison based stemming from the +87% posted in Q1 2018) and iii/ down 5% at subsidiaries in Europe (vs 0% in Q1 / continued pressure in Spain). This decline primarily stemmed from France were sales were down 12.0%. Excluding France, sales were up 3.5%.For H1, consolidated sales were down 8.5% (-9.2% ...

Christophe-Raphaël Ganet

Boiron : La France pénalise le CA T2. Une guidance de ROC en forte baisse. Visibilité toujours très limitée. Prévisions et OC abaissés

>T2 : -6,4%, essentiellement en raison de la France - Le CA T2 affiche un recul de 6,4% (67,2% à tcc) : i/ la France est en baisse de 12% (-9% au T1), ii/ les USA sont en hausse de 14% (vs 0% au T1 qui subissait un fort effet de base compte tenu du +87% enregistré au T1 2018), iii/ les filiales Europe sont en baisse de 5% (vs 0% au T1 / poursuite de la pression en Espagne). Cette baisse provient donc essentiellement de la France où les ventes ont reculé de 12,0 %. Hor...

Christophe-Raphaël Ganet

Boiron : Boiron: unfavourable opinion from the health authority on reimbursement in France

>An unfavourable opinion on maintaining reimbursements for homoeopathy in France - In a press release, Boiron this morning announced that the health authority had handed down an unfavourable opinion on the reimbursement of homoeopathic treatments in France.This morning the health authority is due to hold a press conference and Boiron will hold its own press conference at 11.00 a.m.A very significant and potentially multi-annual impact - The minis...

1 director bought

A director at Boiron bought 441 shares at 68.800EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

Christophe-Raphaël Ganet ...
  • Jean-François Granjon
  • Philippe Ourpatian

ODDO BHF Small & MIDCAP MORNING NEWS - 06/28/2019

We are initiating coverage of SMCP, one of the world leaders in accessible luxury with a Buy recommendation and a target price of € 20.5. The group is known for delivering steady growth in each of its three brands. Taking the best of both worlds, it combines the benefits of luxury and fast fashion. We see the current valuation as an investment opportunity (EV/EBITDA 2019 of 6.3x, 30% discount vs. peers) in light of the group’s solid financial profile and significant growth potential, ...

Christophe-Raphaël Ganet ...
  • Jean-François Granjon
  • Philippe Ourpatian

ODDO BHF Small & MIDCAP MORNING NEWS - 28/06/2019

Nous initions la couverture de SMCP, un des leaders mondiaux du luxe abordable avec une recommandation Achat et un OC de 20.5 €. Le groupe se caractérise par une croissance pérenne sur chacune de ses trois marques en prenant le meilleur de deux mondes, le Luxe et la Fast-fashion. La valorisation actuelle nous semble être une opportunité (6.3x VE/EBITDA 2019e, décote de 30% vs pairs) sur ce dossier dont le profil financier est de qualité et le potentiel de croissance important, en part...

Christophe-Raphaël Ganet ...
  • Emmanuel Matot
  • Laurence Hofmann

ODDO BHF Small & MIDCAP MORNING NEWS - 05/20/2019

...

Christophe-Raphaël Ganet ...
  • Emmanuel Matot
  • Laurence Hofmann

ODDO BHF Small & MIDCAP MORNING NEWS - 20/05/2019

...

Charles Lepetitpas ...
  • Christophe-Raphaël Ganet
  • Nicolas David
  • Salma Bouraoui

ODDO BHF Small & MIDCAP MORNING NEWS - 04/29/2019

In 2018, big question marks were hanging over Spie's deleveraging profile; but, thanks to its full-year results, the group was able to reassure the market over its FCF generation capacity. FCF generation should indeed remain buoyant in 2019, enabling the group to bring down its debt burden and risk profile, and at the same time pursue a bolt-on external growth policy. The group’s current valuation reveals an undeniable value dimension: FCF yield is set to stand at over 10% in 2019 and...

Increased risk weighs on BOIRON SA, penalising its rating down to Slightly Negative

The independent financial analyst theScreener just lowered the general evaluation of BOIRON SA (FR), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title still shows 1 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date June 21, 2019, the closing price was EUR 37.35 and its target price was estimated at EUR 35.48.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Florian Béchaz

Boiron - Assemblée Générale des actionnaires du 16 mai 2019

Proxinvest attire l'attention des actionnaires sur deux points importants : Tout d'abord le conseil d'administration a un taux d'indépendance extrêmement faible avec 7,69% d'après Proxinvest. A ce moment-là Proxinvest regrette que la fin des mandats des trois administrateurs renouvelés cette année n'ait pas entrainé un sursaut de la société pour nommer en lieu et place des administrateurs indépendants. Ensuite le manque de communication des rémunérations est un grave manquement de la part de la société qui empêche les actionnaires d'avoir une vision globale des montants en jeu et de l'exigen...

Jehanne Leroy

Proxy Report - 17/05/2018

Proxinvest attire l'attention des actionnaires sur deux points importants : Tout d'abord le conseil d'administration a un taux d'indépendance extrêmement faible avec 8,33% d'après Proxinvest. A ce moment-là Proxinvest regrette que la fin des mandats des trois administrateurs renouvelés cette année n'ait pas entrainé un sursaut de la société pour nommer en lieu et place des administrateurs indépendants. Ensuite le manque de communication des rémunérations est un grave manquement de la part de la société qui empêche les actionnaires d'avoir une vision globale des montants en jeu et de l'exigen...

Boiron 2014

​Geol analyses are ESG (Environment, Social, Governance) analyses covering European large caps and small and mid caps, listed or non-listed. Those analyses, based on the ESG risks identified, show the qualitative and quantitative performance of issuers, in a ten-page synthesis.

SRI Quantitative KPIs

Les analyses Gaïa sont des analyses ESG (Environnement, Social, Gouvernance) dediees aux entreprises de tailles intermediaires (PME, ETI) françaises. Elles presentent 120 indicateurs quantitatifs sur les trois derniers exercices.

Matthieu DRIOL

Short term view - BOIRON SA : The background trend is clearly bearish.

The background trend is clearly bearish. The movement goes on. The next target is at €51.85, then €50.19. Passing €68.90 would question the continuation of the fall.

Matthieu DRIOL

Analyse court terme - BOIRON SA : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 51,85 €, puis 50,19 €. Le franchissement de 68,90 € remettrait en cause la suite de la baisse.

Matthieu DRIOL

Short term view - BOIRON SA : The movement goes on.

The background trend is clearly bearish. The movement goes on. The next target is at €51.85, then €50.19. Passing €68.90 would question the continuation of the fall.

Matthieu DRIOL

Analyse court terme - BOIRON SA : Le mouvement se poursuit.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 51,85 €, puis 50,19 €. Le franchissement de 68,90 € remettrait en cause la suite de la baisse.

Matthieu DRIOL

Medium term view - BOIRON SA : The movement goes on.

The background trend is clearly bearish. The movement goes on. The next target is at €51.85, then €41.74. Passing €88.94 would question the continuation of the fall.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch